Email: andreas.romaine@medisin.uio.no
Group leader and senior scientist at the Institute for Surgical Research.
Funding
Scientia post-doctoral fellowship & KG Jebsen grant (2021).
Education
Andreas completed his undergraduate education at Imperial College London, gaining a Master’s degree and Bachelor of Science degree in Immunology and Biomedical Research.
He continued his study of integrins, this time in the context of heart disease, completing a PhD in cardiac research at the University of Oslo.
Academic interests
- Studying the activation of cardiac fibroblasts through cell-surface signaling, with a focus on integrin and proteoglycan biology.
- Identification of therapeutic targets of cardiac fibrosis
Research methodologies
- Flow cytometry and cell sorting
- Mass spectrometry
- Advanced light microscopy
Research area
- Cell signaling
- Fibroblast signaling
- Fibrosis
- Heart failure
Latest publications
view all >Sasi A, Romaine A, Erusappan PM, Melleby AO, Hasic A, Dahl CP, Broch K, Almaas VM, Puertas RD, Roderick HL, Lunde IG, Sjaastad I, Vistnes M, Christensen G (2023)
Temporal expression and spatial distribution of the proteoglycan versican during cardiac fibrosis development
Matrix Biol Plus, 19-20, 100135
PubMed 38076279 DOI 10.1016/j.mbplus.2023.100135
Temporal expression and spatial distribution of the proteoglycan versican during cardiac fibrosis development
Matrix Biol Plus, 19-20, 100135
PubMed 38076279 DOI 10.1016/j.mbplus.2023.100135
Vistnes M, Erusappan PM, Sasi A, Nordén ES, Bergo KK, Romaine A, Lunde IG, Zhang L, Olsen MB, Øgaard J, Carlson CR, Wang CH, Riise J, Dahl CP, Fiane AE, Hauge-Iversen IM, Espe E, Melleby AO, Tønnessen T, Aronsen JM, Sjaastad I, Christensen G (2023)
Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction
Cardiovasc Res, 119 (10), 1915-1927
PubMed 37216909 DOI 10.1093/cvr/cvad078
Inhibition of the extracellular enzyme A disintegrin and metalloprotease with thrombospondin motif 4 prevents cardiac fibrosis and dysfunction
Cardiovasc Res, 119 (10), 1915-1927
PubMed 37216909 DOI 10.1093/cvr/cvad078
Romaine A, Melleby AO, Alam J, Lobert VH, Lu N, Lockwood FE, Hasic A, Lunde IG, Sjaastad I, Stenmark H, Herum KM, Gullberg D, Christensen G (2022)
Integrin α11β1 and syndecan-4 dual receptor ablation attenuate cardiac hypertrophy in the pressure overloaded heart
Am J Physiol Heart Circ Physiol, 322 (6), H1057-H1071
PubMed 35522553 DOI 10.1152/ajpheart.00635.2021
Integrin α11β1 and syndecan-4 dual receptor ablation attenuate cardiac hypertrophy in the pressure overloaded heart
Am J Physiol Heart Circ Physiol, 322 (6), H1057-H1071
PubMed 35522553 DOI 10.1152/ajpheart.00635.2021
Alam J, Musiime M, Romaine A, Sawant M, Melleby AO, Lu N, Eckes B, Christensen G, Gullberg D (2020)
Generation of a novel mouse strain with fibroblast-specific expression of Cre recombinase
Matrix Biol Plus, 8, 100045
PubMed 33543038 DOI 10.1016/j.mbplus.2020.100045
Generation of a novel mouse strain with fibroblast-specific expression of Cre recombinase
Matrix Biol Plus, 8, 100045
PubMed 33543038 DOI 10.1016/j.mbplus.2020.100045
Herum KM, Romaine A, Wang A, Melleby AO, Strand ME, Pacheco J, Braathen B, Dunér P, Tønnessen T, Lunde IG, Sjaastad I, Brakebusch C, McCulloch AD, Gomez MF, Carlson CR, Christensen G (2020)
Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin
J Am Heart Assoc, 9 (3), e013518
PubMed 32000579 DOI 10.1161/JAHA.119.013518
Syndecan-4 Protects the Heart From the Profibrotic Effects of Thrombin-Cleaved Osteopontin
J Am Heart Assoc, 9 (3), e013518
PubMed 32000579 DOI 10.1161/JAHA.119.013518